Uterine fibroids are common benign tumors in women of reproductive age, mostly seen in women aged 30 to 50 years, with a high incidence of about 50% of benign tumors in women. The cause of uterine fibroids is unknown, but it is generally believed to occur in women with vigorous ovarian function, and some believe it is related to estrogen and progesterone. The main clinical manifestations of fibroids are: pain, uterine bleeding, abdominal mass, increased leucorrhea, pressure symptoms, infertility or miscarriage, and also secondary to anemia. Interventional endovascular treatment is a method of uterine fibroid treatment, which means that the catheter is super-selected to the uterine artery and embolized under the guidance of imaging equipment; after bilateral uterine artery embolization, the uterine body will not cause uterine necrosis due to the presence of other traffic branches, although the blood flow is limited, but the fibroid is a vigorous growth tissue, and the growth can be inhibited due to ischemia and hypoxia, and even variable necrosis, thus achieving the treatment The aim is to treat the fibroids. The incidence of uterine fibroids is high, but the percentage of those requiring clinical treatment is not high. The fibroids are large, larger than 4 cm, have clear signs of compression, or do cause increased menstrual bleeding due to fibroids or preembolization before surgery for huge fibroids. The following is a case of a patient with uterine fibroids treated by endovascular intervention. Figure 1: Internal iliac arteriogram reveals thickened and tortuous right uterine artery as shown by the arrow. Figure 2: Super-selective uterine arteriogram with an abundant blood supply to the uterine fibroids observed. Figure 3: Transcatheter injection of gelatin sponge and embolization of the uterine artery with loss of distal uterine artery flow. Figure 4: Internal iliac arteriogram showing loss of uterine artery flow. Uterine artery embolization therapy is also applicable to the treatment of postpartum uterine bleeding, adenomyosis and progressive cervical cancer, except that cervical cancer requires concurrent administration of chemotherapeutic drugs.